Scope and claims analysis for U.S. Patent 9,951,080 (crystalline hemihydrate of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide)
Executive summary: U.S. Patent 9,951,080 is a solid-state form patent built around a single API stereochemical identity plus two tightly defined physical forms: a freebase hydrate Form C and a crystalline hemihydrate of that same freebase. The claim set is structurally layered: (i) composition of matter to the hemihydrate via lattice/XRD signatures, (ii) composition of matter to hemihydrate via multiple dependent physchem feature sets (XRD subsets, DSC/TGA/moisture sorption, orthorhombic unit cell), (iii) formulation claims that fix the solid form and practical unit strengths (7.5/15/30/45 mg delivery), and (iv) secondary claims to compositions defined by weight percent solid form and to carrier-containing products plus preparation by simple compounding. The practical enforcement core is the ability to show infringement by a generic or CDMO batch that contains the claimed crystalline form and meets the “peaks at X degrees 2θ” characterizations at ~25°C with Cu Kα1, plus the orthorhombic P212121 lattice parameters, or “substantially as shown” characterization figures.
What does U.S. Patent 9,951,080 claim: crystalline hemihydrate vs freebase hydrate Form C?
Direct answer: The independent claim family anchors on (3S,4R)-3-ethyl-4-(imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in specific hydrated crystalline states. Claim 1 is a crystalline hemihydrate, while Claim 6 identifies the Freebase Hydrate Form C; dependent Claims 2-5 define additional XRD peak subsets for the hemihydrate. Independent Claim 13 and dependent Claim 16 cover freebase hydrate Form C compositions and formulations; Claims 21-30 expand to the hemihydrate solid-state form and carrier formulations plus compounding processes.
Claim 1: “crystalline hemihydrate” of the specific stereochemical API
- Scope anchor: The API identity is fully specified by stereochemistry and substitution pattern:
- (3S,4R) at the pyrrolidine ring
- 3-ethyl substitution
- 4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)
- N-(2,2,2-trifluoroethyl) carboxamide (N-substituted carboxamide)
- Form anchor: “crystalline hemihydrate” (water content: hemihydrate implied).
Claim construction impact: Because Claim 1 does not recite explicit XRD/DSC/TGA thresholds, it is still limited by the specification’s disclosure and the “crystalline hemihydrate” characterization described through later dependent claims and the figures. For infringement practice, Claim 1 becomes the broadest “form” hook; the narrowness typically shows up in dependent claims that recite peak lists and unit cell parameters.
Claim 6: explicit naming of the hydrate form
- Claim 6 defines Claim 1’s hemihydrate as:
- “Freebase Hydrate Form C of [the same API]”
Scope consequence: If “crystalline hemihydrate of Claim 1” is equated to “Freebase Hydrate Form C,” then the patent is treating Form C as a crystalline hemihydrate rather than some other hydration state (e.g., monohydrate, anhydrate, amorphous, solvate mix). That makes Form-C identity a central infringement lever.
What X-ray diffraction (XRPD) peaks define infringement risk under claims 2-5 and 7?
Direct answer: The hemihydrate is characterized by Cu Kα1 (monochromatic) XRPD peaks near specific 2θ values at ~25°C. Claims 2-5 create several alternative peak-pattern “windows” that map to the same underlying form, and Claim 7 further uses “substantially as shown in FIG. 3C,” creating a figure-based infringement route.
Claim 2: three-peak pattern
Peaks at:
- 13.4 ± 0.2°
- 15.1 ± 0.2°
- 21.7 ± 0.2°
(measured at about 25°C; monochromatic Kα1)
Claim 3: four-peak pattern (adds 17.0 ± 0.2°)
- 13.4 ± 0.2
- 15.1 ± 0.2
- 17.0 ± 0.2
- 21.7 ± 0.2
Claim 4: four-peak pattern (adds 20.9 ± 0.2°)
- 13.4 ± 0.2
- 15.1 ± 0.2
- 20.9 ± 0.2
- 21.7 ± 0.2
Claim 5: six-peak pattern (densest)
- 13.4 ± 0.2
- 15.1 ± 0.2
- 15.5 ± 0.2
- 17.0 ± 0.2
- 20.9 ± 0.2
- 21.7 ± 0.2
Claim 7: “substantially as shown in FIG. 3C”
This is a second “meter stick” beyond numeric peak lists.
Enforcement mechanics: Numeric peaks (Claims 2-5) are objective and easier to benchmark in XRPD datasets. Figure-based language (Claim 7) typically broadens how closely accused material must match the patent pattern, depending on how the claim is interpreted against the specification.
Risk note for competitors: If an accused solid includes the claimed hemihydrate as a major component, they may still be vulnerable if their XRPD exhibits the required peak set within the stated ±0.2° windows.
How do DSC/TGA/moisture sorption claims narrow the crystalline hemihydrate definition?
Direct answer: Claims 8-11 add orthogonal confirmation modes beyond XRPD: thermogravimetric analysis, differential scanning calorimetry endotherm timing, and moisture sorption isotherm shape. These are supportive for infringement mapping because they reduce the chance that a different hydrate/solvate mimics the same XRPD peaks.
Claim 8: TGA profile “substantially as shown in FIG. 4E”
- “thermogravimetric analysis profile substantially as shown”
Claim 9: DSC profile “substantially as shown in FIG. 5C”
- “differential scanning calorimetry profile substantially as shown”
Claim 10: DSC endotherm window
- endotherm between 120°C and 170°C
- measured at 10°C/min
Claim 11: moisture sorption isotherm profile
- “substantially as shown in FIG. 6B”
Practical effect: A generic form-maker can sometimes engineer around XRPD by producing a structurally related polymorph/hydrate with altered diffraction. The patent’s multi-modality characterization makes such “lookalike” avoidance harder, because the accused material must also fit (or avoid fitting) the DSC/TGA/moisture signatures as construed.
What crystallographic lattice constraints are in the patent: P212121 with unit cell a/b/c?
Direct answer: Claim 12 hard-frames the lattice as orthorhombic with space group P212121 and unit cell parameters near a ≈ 12.7 Å, b ≈ 13.1 Å, c ≈ 22.6 Å.
Claim 12: orthorhombic lattice and unit cell parameters
- orthorhombic lattice type
- P212121 space group
- unit cell:
- a = about 12.7 Å
- b = about 13.1 Å
- c = about 22.6 Å
Enforcement mechanics: Lattice parameters are strong discriminators. Even if an accused sample produces the required “headline” XRPD peaks, space group and unit cell alignment can be decisive in validity and infringement disputes.
What formulation protections exist for the crystalline hemihydrate (Claims 16-20, 24-28)?
Direct answer: The patent covers carrier-containing pharmaceutical compositions that specify the solid state form and then recites practical unit delivery strengths: 7.5 mg, 15 mg, 30 mg, and 45 mg of the API.
Freebase Hydrate Form C formulations
- Claim 16: pharmaceutical composition comprising Freebase Hydrate Form C + pharmaceutically acceptable carrier
- Claims 17-20: carrier formulations with delivery amounts sufficient to deliver:
- ~7.5 mg (Claim 17)
- ~15 mg (Claim 18)
- ~30 mg (Claim 19)
- ~45 mg (Claim 20)
Crystalline hemihydrate formulations
- Claim 24: pharmaceutical composition comprising crystalline hemihydrate (Claim 2) + carrier
- Claims 25-28: formulations with delivery amounts sufficient to deliver:
- ~7.5 mg (Claim 25)
- ~15 mg (Claim 26)
- ~30 mg (Claim 27)
- ~45 mg (Claim 28)
Scope note: These claims are “form fixed, amount specified.” They are not limited to dosage form (tablets/capsules), and the “amount sufficient” wording typically ties to how the dosing unit is formulated rather than a device type. That widens product coverage.
How much “solid form purity” is required: the 75% and 95% weight thresholds?
Direct answer: The patent includes purity thresholds that target mixtures where the claimed solid form is the dominant phase.
Freebase hydrate Form C purity
- Claim 14: at least about 75% by weight
- Claim 15: at least about 95% by weight
Crystalline hemihydrate purity
- Claim 22: at least about 75% by weight
- Claim 23: at least about 95% by weight
Infringement posture: These thresholds allow the patentee to pursue accused products that may include minor amounts of other hydrates/polymorphs, as long as the claimed form dominates by weight.
How broad are the “composition of solid state form” claims (13, 21) and do they cover mixtures?
Direct answer: Claim 13 is a composition defined by the solid state form itself (Form C) with no explicit purity threshold. Claim 21 is similar for the crystalline hemihydrate defined by claim 2, with explicit purity thresholds in dependent claims.
Claim 13: solid state form = Freebase Hydrate Form C
- “composition comprising a solid state form, wherein the solid state form is Freebase Hydrate Form C”
Claim 21: solid state form = crystalline hemihydrate of claim 2
- “composition comprising a solid state form, wherein the solid state form is the crystalline hemihydrate of claim 2”
Mixture coverage: Independent “composition” claims typically cover the named solid form itself and can reach mixtures if construed as still having the required crystalline form. Dependent claims (14-15, 22-23) reduce ambiguity by specifying weight % dominance.
What process claims exist, and are they meaningful for generic design-around?
Direct answer: The patent includes two “compounding” style process claims that recite combining the claimed solid form with a pharmaceutically acceptable carrier. These are typically low-barrier and less protective than true manufacturing process claims, but they can support method-based infringement for formulation steps.
Claim 29: process for preparing the composition of Claim 16
- combining Freebase Hydrate Form C with carrier
Claim 30: process for preparing the composition of Claim 24
- combining crystalline hemihydrate with carrier
Design-around: If the competitor avoids producing/using the claimed solid form (e.g., uses a different hydrate/polymorph or amorphous dispersion), the compounding steps may not land within the process claims.
Patent landscape: what this claim set implies about how the patent estate is positioned
Direct answer: This is a “form-centric” patent that likely sits within a broader crystal engineering program for the same API. Even without the rest of the family text, the claim architecture signals a strategy: lock down (i) the crystalline hemihydrate/Form C, (ii) confirmation attributes (XRPD lattice, DSC/TGA/moisture), and (iii) fixed-form pharmaceutical compositions at clinically relevant strengths.
How to read scope relative to typical solid-state ecosystems
- Base molecule claim coverage (often earlier in a family) is not shown here; this patent is drafted against the form.
- Polymorph/hydrate differentiation is handled through:
- XRPD peak windows (Claims 2-5)
- XRPD figure (Claim 7)
- lattice parameters and space group (Claim 12)
- Product form (formulation) coverage is handled through:
- purity thresholds (Claims 14-15, 22-23)
- carrier-containing formulations (Claims 16, 24)
- “amount sufficient to deliver” strength set (Claims 17-20, 25-28)
- Manufacturing/processing is limited to compounding with carrier (Claims 29-30).
Business consequence: For a generic entrant, the highest-value decision is not only “can we make the API,” but “can we make a different solid form that avoids XRPD/DSC/TGA/moisture/lattice matching,” and still achieve equivalent bioavailability and regulatory acceptability.
Key claim-to-claim relationship map (where scope expands vs narrows)
Claim 1 vs 2-5: Claim 1 establishes the hemihydrate concept without numerical peak lists; Claims 2-5 specify alternative XRPD peak sets that satisfy “crystalline hemihydrate” characterization. This layering supports both broad and evidence-backed infringement theories.
Claim 2-5 vs 12: Numeric peak lists identify a target diffraction fingerprint. Claim 12 ties that fingerprint to a specific orthorhombic lattice and space group.
Claim 8-11: DSC/TGA/moisture are additional proof points that can be used to confirm the same solid-state identity, and they may deter “false positive” defenses based on incomplete XRPD matching.
Claims 13-15 and 16-20 vs Claims 21-23 and 24-28: The patent duplicates the same enforcement scheme for two perspectives:
- Form C (freebase hydrate Form C)
- crystalline hemihydrate (as defined in Claim 2)
Each then becomes a composition and a dosage-ready formulation with the same unit strength set.
Claims 14-15, 22-23: Purity thresholds create multiple infringement “lanes” depending on how a competitor controls phase composition.
Key takeaways
- U.S. Patent 9,951,080 is designed to protect a single API’s specific crystalline hemihydrate, treated as Freebase Hydrate Form C, using layered solid-state identifiers.
- The infringement core is the combination of:
- stereochemically defined API identity
- XRPD peak windows at ~25°C (Claims 2-5) and figure-based XRPD (Claim 7)
- orthorhombic lattice with P212121 and unit cell parameters (Claim 12)
- supporting confirmation tests (TGA/DSC/moisture) (Claims 8-11)
- The patent extends protection to carrier formulations at 7.5, 15, 30, and 45 mg delivery amounts, plus purity-threshold compositions (≥75% and ≥95% by weight).
- Process claims are compounding-oriented (combine the named solid form with carrier), so design-around primarily depends on avoiding the claimed solid state.
FAQs
1) Do the XRPD peak lists in Claims 2-5 require all listed peaks at once for infringement?
Claim language is claim-by-claim: each dependent claim defines a particular peak set. A sample matching one dependent claim’s peak subset can support infringement of that dependent claim if the other claim elements are met.
2) Can a formulation still infringe if the product contains other hydrates or polymorphs besides the claimed hemihydrate?
Yes, if the formulation meets the composition claims with weight % thresholds (Claims 14-15, 22-23) or if the solid form characterization is found in the accused material consistent with the asserted claim scope.
3) What is the practical role of Claim 12’s space group and unit cell parameters?
It provides a crystallographic “hard stop” that helps distinguish the claimed hemihydrate from structurally similar hydrate forms that may share some diffraction features.
4) Are the “amount sufficient to deliver 7.5/15/30/45 mg” terms limited to a specific dosage form like tablets?
The claims specify delivery amounts in the pharmaceutical composition; they do not expressly limit to a particular dosage form, so the protective scope typically tracks unit dose strength irrespective of tablet/capsule form factor.
5) Do Claims 29-30 create meaningful manufacturing barriers for generic entrants?
They can support liability for compounding steps using the claimed solid form with a carrier, but they do not, by themselves, impose specialized synthesis/manufacturing controls beyond obtaining and using the claimed solid state form.
References
No external sources were provided in the prompt, and no patent bibliographic data (filing date, assignee, priority, publication number, prosecution history, or expiration) was supplied. No citations are included.
